Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan reiterates 'overweight' rating on Relx, raises legal growth expectations

(Sharecast News) - Analysts at JPMorgan upgraded their legal growth expectations for Relx to 10% per year in order to reflect a bigger total addressable market for Agentic AI. JPMorgan said it had previously interpreted Relx's expectation for legal growth "to accelerate over the next decade" as growth accelerating from 7% to roughly 8-8.5% over the next three years.

However, JPM now believes the market opportunity to be "much more profound" than it had first anticipated, noting that it may have captured the upside from AI helping customers get more value from Lexis' existing information and tools, and the enhanced value from Protege's personalisation, but failed to capture the opportunity for Lexis to leverage Agentic AI to provide legal execution and drive a multiplication of its addressable market.

"We believe we have also underestimated the scope for AI to drive internal efficiencies and improve the return on product investment - AI not only expands the TAM but makes it easier for Lexis to address it with the faster and cheaper development of new products," said JPM.

"We upgrade our 10-year legal growth to 10% - and would be surprised if Lexis does not see periods of faster growth. An initial transactional model for Protégé modules could pull forward the acceleration."

JPM upgraded its legal valuation by another 20-25% and Relx's overall group valuation from 4,630.0p to 4,890.0p as it reiterated its 'overweight' rating on the stock.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.